An animal demonstrated that combination therapy with a CD40 agonist resulted in a superior effector response compared to anti-PD-1 monotherapy for CCA, accompanied by an increased presence of CD4+ T and CD8+ T cells in tumor-bearing mice (180). This evidence concerns the gene CD4 and cholangiocarcinoma.